Atezolizumab Archives - Medical Conferences

Benefit of adjuvant atezolizumab/bevacizumab in HCC not maintained over time

Presented By

Dr Adam Yopp, UT Southwestern Medical Center, TX, USA

Trial

Phase 3, IMbrave050

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 13:13

Final OS for CONTACT-02 trial in mCRPC

Presented By

Prof. Neeraj Agarwal, Huntsman Cancer Institute; University of Utah, UT, USA

Trial

Phase 3, CONTACT-02

Conference

ESMO 2024

Type

Peer-reviewed article

4 November 2024 11:30

High survival rates following atezolizumab consolidation in DLBCL

Presented By

Dr Marcel Nijland, University Medical Center Groningen, the Netherlands

Trial

Phase 2, HOVON 151

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:27

Superior OS with atezolizumab plus bevacizumab versus lenvatinib in unresectable HCC

Presented By

Dr Sangdao Boonkaya, King Chulalongkorn Memorial Hospital, Thailand

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 11:46

IMmotion010 trial: KIM-1 and disease-free survival in RCC

Presented By

Prof. Laurence Albiges, Institut Gustave Roussy, France

Trial

Phase 3, IMmotion010

Conference

ASCO 2024

13 June 2024 15:07

SKYSCRAPER-08: Adding tiragolumab to oesophageal cancer regimen improves outcomes

Presented By

Prof. Chih-Hung Hsu, National Taiwan University Hospital, Taiwan

Trial

Phase 3, SKYSCRAPER-08

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:17

Atezolizumab improves pCR in HER2-positive early breast cancer

Presented By

Dr Luca Gianni, IRCCS Ospedale San Raffaele, Italy

Trial

Phase 3, APTneo

Conference

SABCS 2023

Type

News article

11 January 2024 15:00

Addition of atezolizumab to chemotherapy and maintenance PARP inhibitor has no benefit in ovarian cancer

Presented By

Prof. Antonio Gonzalez Martin, Cancer Centre Clinica Universidad de Navarre, Spain

Trial

Phase 3, ANITA

Conference

ESMO 2023

Type

Peer-reviewed article

19 December 2023 12:43

The importance of detecting early NSCLC

Expert

Prof. Witold Rzyman, Medical University of Gdańsk, Poland

Conference

ESMO 2023

20 November 2023 15:34

Exploratory analysis of IMvigor130 trial finds no OS benefit from atezolizumab in subgroups

Presented By

Dr Enrico Grande, MD Anderson Cancer Center, Spain

Trial

Phase 3, IMvigor130

Conference

ASCO 2023

Type

Peer-reviewed article

2 August 2023 09:08

IMbrave 151 missed primary endpoint in advanced BTC

Presented By

Prof. Anthony El-Khoueiry, USC Norris Comprehensive Cancer Center, CA, USA

Trial

Phase 2, IMbrave151

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 09:15

Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence

Presented By

Dr Axel Bex, The Royal Free London NHS Foundation Trust, UK

Trial

Phase 3, IMmotion-010

Conference

ESMO 2022

Type

Peer-reviewed article

17 November 2022 00:28

IMpower010: First interim OS analysis of adjuvant atezolizumab in NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

Phase 3, IMpower010

Conference

WCLC 2022

Type

News article

23 August 2022 11:02

Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma

Presented By

Prof. Jürgen Gschwend, Technical University Munich, Germany

Trial

Phase 3, IMvigor010

Conference

EAU 2022

Type

News article

22 July 2022 12:26

Atezolizumab does not improve survival in advanced penile cancer

Presented By

Dr Hielke-Martijn de Vries, Netherlands Cancer Institute, the Netherlands

Trial

Phase 2, PERICLES

Conference

ASCO GU 2022

Type

Peer-reviewed article

8 April 2022 11:11

Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC

Presented By

Dr Hyeyeong Kim, Ulsan University Hospital, South Korea

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 10:00

ASCO GU 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GU 2022

14 March 2022 07:21

Single-cell spatial analysis can predict response to neoadjuvant immunotherapy

Presented By

Dr Giampaolo Bianchini, Ospedale San Raffaele, Italy

Trial

Phase 3, NeoTRIPaPDL1

Conference

SABCS 2021

Type

Peer-reviewed article

31 January 2022 17:48

Immune chemo-sensitisation looks promising in microsatellite-stable mCRC

Presented By

Dr Filippo Pietrantonio, Istituto Nazionale dei Tumori di Milano, Italy & Dr Chiara Cremolini, Azienda Ospedaliero-Universitaria Pisana, Italy

Trial

Phase 2, MAYA & AtezoTRIBE

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:42

Adjuvant atezolizumab lowers relapse rate in resected NSCLC

Presented By

Dr Enriqueta Felip, Vall d’Hebron Institute of Oncology, Spain

Trial

Phase 3, Impower010

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:35

Atezolizumab promising for treating NSCLC brain metastases

Presented By

Prof. Ernest Nadal, Catalan Institute of Oncology, Spain

Trial

Phase 2, ATEZO-BRAIN

Conference

WCLC 2021

Type

News article

21 September 2021 13:24

Real-world data shows inferior survival compared with IMpower150 results

Presented By

Dr Samantha Dean, Austin Health, Australia

Trial

Phase 3, IMpower150

Conference

WCLC 2021

Type

News article

21 September 2021 13:23

Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma

Presented By

Prof. Anne Tsao, MD Anderson Cancer Center, TX, USA

Conference

WCLC 2021

Type

News article

21 September 2021 13:23

ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer

Presented By

Prof. Jürgen Gschwend, Technical University Munich, Germany

Trial

Phase 3, IMvigor010, IMvigor011

Conference

EAU 2021

Type

Peer-reviewed article

31 August 2021 12:26

Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC

Presented By

Dr Mark Socinski, AdventHealth Cancer Institute, FL, USA

Trial

Phase 3, IMpower130, IMpower132, IMpower150

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 22:02

Atezolizumab with SABR for high-risk early-stage NSCLC: initial results

Presented By

Prof. Arta Monjazeb & Prof. Karen Kelly, UC Davis

Journal

Physician's Weekly

Conference

ASCO 2020

13 April 2021 18:56

Landmark OS for HCC, updated IMbrave150 data

Presented By

Prof. Richard Finn, UCLA, USA

Trial

Phase 3, IMbrave150

Conference

ASCO GI 2021

Type

Peer-reviewed article

12 March 2021 11:39

Neoadjuvant treatment in patients with high-risk early breast cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:19

Contradicting results for chemoimmunotherapy in metastatic TNBC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 16:01

Preoperative immunotherapy in early stage NSCLC safe and feasible

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:07

PD-L1 density, a new predictive biomarker in NSCLC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:59

Atezolizumab/bevacizumab for non-squamous NSCLC with high PD-L1 expression

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:58

First-line treatment of advanced/metastatic RCC

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:44

First-line immune-combination therapies in mUC

Trial

Phase 3, KEYNOTE-361

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:43

Treatment of newly diagnosed ovarian cancer

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 14:39

Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma

Expert

Dr Maya H.A. Hussain, Northwestern University in Chicago, IL, USA

Trial

Phase 3, IMvigor010

Conference

ASCO 2020

Type

Peer-reviewed article

17 September 2020 13:57

No higher pathologic complete response with atezolizumab added to chemotherapy

Trial

IMpassion130

Conference

SABCS 2019

Type

Peer-reviewed article

13 February 2020 23:54

PFS extension with immunotherapy + chemotherapy in urothelial cancer

Presented By

Dr Enrique Grande, MD Anderson Cancer Centre Madrid, Spain

Trial

IMvigor130

Conference

ESMO 2019

Type

Peer-reviewed article

26 November 2019 21:24

Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC

Trial

Phase 3, IMpower 131

Conference

WCLC 2019

Type

Peer-reviewed article

8 November 2019 21:25

ImPassion130 brings breast cancer into the immunotherapy era

Trial

Phase 3, ImPassion130

Conference

ASCO 2019

Type

Peer-reviewed article

15 July 2019 11:27

Combo I-O plus chemotherapy

Presented By

Dr Luis Paz-Ares, Complutense University of Madrid, Spain

Trial

Keynote-189, Impower-132

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 22:15

Other I-O combinations

Presented By

Prof. Solange Peters, Lausanne University Hospital and Ludwig Institute, Switzerland

Trial

IMpower 150

Conference

ELCC 2019

25 June 2019 21:17

Treatment options in early NSCLC

Presented By

Dr Walter Weder, Dr Raffaele Califano

Trial

CALGB 9633

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 13:04

Immunotherapy in SCLC: trial data

Presented By

Dr Enriqueta Felip, Vall d’Hebron University Hospital, Spain

Trial

CA184-156, CheckMate-451, CASPIAN, Keynote-604, Checkmate 032

Conference

ELCC 2019

Type

Peer-reviewed article

25 June 2019 08:15

Largest safety study of its kind with atezolizumab in metastatic bladder cancer

Presented By

Prof. Axel Merseburger, Prof. Jens Bedke

Trial

Phase 3, SAUL, IMvigor211

Conference

EAU 2019

21 May 2019 23:38

Bladder cancer in young patients

Presented By

Dr Roland Seiler, Prof. Morgan Rouprêt, Prof. Fiona Burkhard

Trial

IMvigor 210

Conference

EAU 2019

Type

Peer-reviewed article

21 May 2019 19:55

Combination therapies: Where are we in 2018?

Presented By

Prof. Martin Reck, German Center for Lung Research, Germany

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 22:05

New standard of care in extensive-stage small-cell lung cancer

Presented By

Dr Stephen Liu, Georgetown University Hospital, USA

Trial

IMpower133

Conference

WCLC 2018

Type

Peer-reviewed article

21 November 2018 20:55